Aster DM Quality Care

    ASTERDM
    Pharma
    ₹731.00
    Price as of 18 Nov 2026, 9:58 pm IST

    Market cap ₹63,646 Cr

    P/E
    93.00
    Day range
    ₹728.00 – ₹750.60
    52-week range
    ₹519.10 – ₹891.30
    Volume
    8.66 L
    Open
    ₹739.40
    Prev close
    ₹737.95

    Latest results · Q2 FY27(consolidated)Revenue ₹2,829 Cr+136.3%Profit ₹322 Cr+165.7%Margin 11.4%YoY vs the same quarter last year

    1 red flag to read up on

    • high

      Promoter pledge went up

      66.99% of promoter shares pledged, up from 18.17% · 30 Sept 2026

    From NSE and BSE filings. A flag is a reason to read the filing, not a rating.

    Research profile

    Composite 50 / 100

    Factor percentiles

    Value24
    Quality45
    Momentum47
    Low volatility83

    Derived metrics

    Earn. yield
    1.1%
    Graham no.
    ₹110.70
    vs Graham
    -84.9%
    ROE ÷ P/B
    1.5%
    12-1 mom.
    -1.1%
    Return / vol
    0.25
    Magic Formula
    #557
    Piotroski
    4/6
    FCF yield
    0.3%

    Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.

    Peer comparison

    All 68 in Pharma
    Largest Pharma companies tracked, with sector medians
    CompanyM-capP/EP/BROEROCEOPMD/ESales YoY
    Sun PharmaSUNPHARMA₹4.49 L Cr40.955.0314.8%21.0%29.0%0.04+11.9%
    Divi's LaboratoriesDIVISLAB₹2.93 L Cr87.1916.8816.2%22.0%43.0%0.00+35.4%
    Torrent PharmaTORNTPHARM₹1.75 L Cr77.889.6726.8%15.0%33.0%0.77+50.8%
    Apollo HospitalsAPOLLOHOSP₹1.27 L Cr56.4011.5522.6%17.0%16.0%0.77+23.0%
    Laurus LabsLAURUSLABS₹1.25 L Cr93.7219.8218.2%18.0%34.0%0.43+33.5%
    Zydus LifesciencesZYDUSLIFE₹1.20 L Cr28.724.3220.1%21.0%24.0%0.50+29.2%
    Dr. Reddy's LabsDRREDDY₹1.17 L Cr41.632.9711.6%13.0%20.0%0.19-1.5%
    Aster DM Quality CareASTERDM₹63,646 Cr93.008.0811.8%12.0%23.0%0.76+136.3%
    Sector median₹24,603 Cr43.685.4615.1%17.0%24.0%0.17+22.7%

    Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.

    Latest news

    Updated 9h ago

    Headlines about Aster DM Quality Care from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.

    Key metrics

    P/E (TTM)
    122.0
    Price / Book
    8.18
    ROE (FY26)
    11.8%
    ROCE (latest year)
    12%
    Dividend yield
    0.41%

    Moving averages (NSE)

    20-day
    ₹696.59
    Price above
    50-day
    ₹715.93
    Price above
    200-day
    ₹721.52
    Price above

    Charts & trends

    From company filings. Amounts in ₹ crore.

    Revenue 3Y CAGR
    +15.7%
    Profit 3Y CAGR
    -3.5%
    Revenue YoY (Sep 2026)
    +136.3%
    Profit YoY (Sep 2026)
    +166.1%
    Operating margin
    23.0%
    Net margin
    11.4%

    Revenue, profit & margin - quarterly

    ₹ crore; a loss shows red. Operating margin below, same periods.

    -2K Cr0 Cr2K Cr4K Cr6K Cr
    • Revenue
    • Net profit

    Operating margin

    Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Sep 20260%15%30%

    Who owns the company

    % of equity by quarter, latest Sept 2026

    Dec '24Mar '25Jun '25Sept '25Dec '25Mar '26Jun '26Sept '260%25%50%75%100%
    • Promoter
    • DII
    • FII
    • Public
    • Others

    Cash flows

    Where cash came from and went, by fiscal year (₹ crore)

    Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-10K Cr-5K Cr0 Cr5K Cr10K Cr
    • Operating
    • Investing
    • Financing
    • Free cash flow

    Return on equity

    Net profit over shareholders' equity, by fiscal year

    FY17FY18FY19FY20FY21FY22FY23FY24FY25FY260%50%100%150%15% screen

    Equity vs debt

    Shareholders' equity against borrowings (₹ crore); the ratio below, same years.

    0 Cr2K Cr4K Cr6K Cr8K Cr
    • Equity
    • Debt

    Debt to equity

    Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 20260x1x2x

    Dividends per share

    ₹ by fiscal year of the ex-date; the latest year runs to date.

    FY25FY26FY27₹0₹50₹100₹150

    Financial statements

    ₹ Crore
    Quarterly results, oldest period first, figures in rupees crore
    Line itemDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
    Sales9559741,0021,0861,0501,0001,0781,1971,1861,1821,3112,829
    YoY Sales growth-70———————————
    Expenses8058178418698648188769619839581,0552,174
    Operating Profit149156161217186182202236202224256655
    OPM %16%16%16%20%18%18%19%20%17%19%20%23%
    Other Income153-405,12035952928037-7733
    Interest2530293131323131313031119
    Depreciation5758606262646366686769150
    Profit before tax220285,1911591029113616710316378419
    Tax %5%108%1%33%37%6%31%27%43%6%62%23%
    Net Profit209-25,1521066486941215915429322
    EPS in Rs₹3.59₹-0.48₹103.00₹1.94₹1.14₹1.58₹1.65₹2.12₹1.01₹2.71₹0.31₹3.01

    From company filings, updated 19 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.

    Working-capital cycle

    Debtor Days24

    -62 days since Mar 2021

    Inventory Days32

    -90 days since Mar 2021

    Days Payable168

    -122 days since Mar 2021

    Cash Conversion Cycle-112

    -29 days since Mar 2021

    Working Capital Days-28

    -33 days since Mar 2021

    Strengths, risks & growth

    Aster DM Healthcare Limited is one of the largest integrated private healthcare service providers operating in GCC (Gulf Cooperation Council) countries and an emerging player in India. With an inherent emphasis on clinical excellence, it is one of the few entities in the world with a strong presence across primary, secondary, tertiary and quaternary healthcare. [1]

    Strengths

    • Company is expected to give good quarter
    • Company has been maintaining a healthy dividend payout of 1,560%
    • Promoter holding has increased by 13.4% over last quarter.

    Risks

    • Stock is trading at 8.18 times its book value
    • Company has a low return on equity of 8.46% over last 3 years.
    • Company might be capitalizing the interest cost
    • Promoters have pledged 67.0% of their holding.

    Compounded Sales Growth

    10 Years
    -1%
    5 Years
    -12%
    3 Years
    +16%
    TTM
    +50%

    Compounded Profit Growth

    10 Years
    +48%
    5 Years
    +23%
    3 Years
    -1%
    TTM
    +43%

    Stock Price CAGR

    10 Years
    —
    5 Years
    +30%
    3 Years
    +29%
    1 Year
    +10%

    Return on Equity

    10 Years
    +9%
    5 Years
    +10%
    3 Years
    +8%
    Last Year
    +11%

    Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.

    Shareholding pattern

    Percentage of shares held by each category at each quarter end
    HolderDec 2025Mar 2026Jun 2026Sept 2026Change
    Promoter40.39%40.39%40.39%53.78%+13.39 pp
    FII18.46%17.18%10.53%12.26%+1.73 pp
    DII26.12%27.57%27.65%21.66%-5.99 pp
    Public14.80%14.61%21.41%12.17%-9.24 pp
    Others0.23%0.23%0.00%0.11%+0.11 pp

    Filed with NSE for Sept 2026: promoters 53.79%, public 46.10%

    Analysts & fund holdings

    100%
    100% recommend buy
    12 analysts cover the stock
    Valuation vs Health Care Providers & Services
    P/E93.0 vs 45.2
    Sector P/B6.05
    Beta0.82

    Who holds the shares, quarter by quarter

    Mutual funds 20.79% (+4.86 pp)
    Sept 25
    Dec 25
    Mar 26
    Jun 26
    Jul 26
    Sept 26
    • Promoters53.9%
    • Foreign institutions12.3%
    • Mutual funds20.8%
    • Insurance0.7%
    • Other domestic institutions0.2%
    • Retail1.8%
    • Others10.3%
    Mutual funds holding the most
    Fund% of company% of fund3-month change
    HDFC Small Cap Fund2.06%3.45%-0.44 pp
    Kotak Mid Cap Fund1.58%1.59%+0.49 pp
    HDFC Mid Cap Fund1.49%0.96%+0.54 pp
    HDFC Focused Fund1.40%3.44%+3.44 pp
    HDFC Flexi Cap Fund1.25%0.75%+0.09 pp

    Scorecard

    Performance
    Avg
    Valuation
    High
    Growth
    Low
    Profitability
    High
    Entry point
    Good
    Red flags
    Avg

    Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.

    Risk & trend

    From 292 daily sessions to 18 Nov 2026.

    Computed

    Risk

    Volatility (1Y)
    29.3%
    Downside volatility
    27.7%
    Worst 5% of days
    2.8%
    Average of that tail
    3.7%
    Max drawdown (1Y)
    25.9%
    Below its peak
    15.9%

    Against the market

    Beta vs Nifty 50
    0.41
    Correlation
    0.19
    Relative strength (3M)
    -14.7%
    ATR (14)
    3.4%

    Return

    Return 1M
    +8.4%
    Return 3M
    -10.8%
    Return 6M
    -3.2%
    Return 1Y
    +7.2%
    vs 200-day average
    +1.3%

    Momentum

    RSI (14)
    56.5
    MACD histogram
    7.01
    Stochastic %K
    70.2
    ADX (14)
    29.3
    +DI / −DI
    21.6 / 9.8
    Money flow index
    72.4

    Participation

    Delivery (20d avg)
    56.2%
    vs its 60-day baseline
    -1.8 pts
    Volume vs 20-day
    -0.3σ
    Close vs day's VWAP
    -0.3%
    52-week position
    58 / 100

    These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.

    Financial quality

    From consolidated statements to 30 Sept 2026.

    Computed

    Piotroski F-Score

    4 of 6 tested

    • Return on assets positive — passed
    • Operating cash flow positive — not testableno cash flow statement for this period
    • Return on assets improving — passed
    • Cash flow exceeds profit — not testableneeds cash flow and profit against assets
    • Debt to assets falling — passed
    • Current ratio improving — failed
    • No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
    • Operating margin improving — passed
    • Asset turnover improving — failed
    Free cash flow
    ₹178 Cr
    FCF yield
    0.3%
    Cash conversion
    1.54
    Accruals ratio
    -0.028
    Net debt
    ₹5,164 Cr
    Net debt / equity
    0.66
    EV / sales
    10.57
    Capex intensity
    10.3%
    Revenue CAGR
    99.9%
    Profit CAGR
    142.0%

    Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.

    Insider trades

    Last 12 months, market trades
    Net buying ₹380 Cr
    3 buys · ₹380 Cr
    0 sells · ₹0
    Latest insider trades disclosed to NSE
    PersonTypeSharesValueDisclosed
    Union (Mauritius) Holdings Limited
    Promoter Group · Market Purchase
    Buy91,174₹6.9 Cr2 Sept 2026
    Union (Mauritius) Holdings Limited
    Promoter Group · Market Purchase
    Buy2,95,823₹22.4 Cr2 Sept 2026
    Union (Mauritius) Holdings Limited
    Promoter Group · Market Purchase
    Buy46,09,800₹350 Cr2 Sept 2026

    Disclosures filed with NSE under SEBI (Prohibition of Insider Trading) Regulations. Pledges and releases are not trades and are not counted above.

    Corporate actions

    • dividend
      ₹3.00

      Interim Dividend - Rs 3 Per Share

      2 Apr 2026
      ex-date
    • dividend
      Not available — not reported in this filing

      Dividend - Re 1 Per Share

      28 Aug 2025
      ex-date
    • dividend
      ₹4.00

      Interim Dividend - Rs 4 Per Share

      10 Feb 2025
      ex-date
    • dividend
      ₹2.00

      Annual General Meeting/Dividend - Rs 2 Per Share

      22 Aug 2024
      ex-date
    • dividend
      ₹118.00

      Special Dividend - Rs 118 Per Share

      23 Apr 2024
      ex-date
    • buyback
      Not available — not reported in this filing

      Buy Back

      23 Jan 2020
      ex-date

    Company announcements

    AGM/EGMPrice-sensitive
    Transcript Of The 18Th Annual General Meeting Held On 28 September 2026 Through Video Conferencing ("VC")

    Transcript of the 18th Annual General Meeting held on 28 September 2026 through Video Conferencing ("VC")

    Company Update
    Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    Certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30 September 2026

    AGM/EGMPrice-sensitive
    Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    Submission of e-voting results along with scrutinizers report for the 18th AGM held on 28 September 2026

    Company Update
    Announcement under Regulation 30 (LODR)-Retirement

    Retirement of Ms. Purana Housdurgam Vijayadeepti as Non- Executive Independent Director of the Company with effect from the conclusion of the 18th Annual General Meeting of the Company

    Company Update
    Announcement under Regulation 30 (LODR)-Change in Management

    Change in Directors of the Company

    AGM/EGMPrice-sensitive
    Shareholder Meeting / Postal Ballot-Outcome of AGM

    Summary of Proceedings of the 18th Annual General Meeting held on September 28, 2026 held at 11:30 A.M IST

    Insider Trading / SAST
    Closure of Trading Window

    Intimation of closure of Trading window

    AGM/EGM
    Shareholder Meeting / Postal Ballot-Scrutinizer"s Report

    Disclosure of voting results of the Postal Ballot and submission of Scrutinizer's Report

    AGM/EGM
    Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot

    Disclosure of voting results of the Postal Ballot and submission of Scrutinizer's Report

    Company Update
    Addendum To The Notice Of 18Th Annual General Meeting

    Please find enclosed an Addendum to the Notice of the 18th Annual General Meeting of the Company

    Company UpdatePrice-sensitive
    Announcement under Regulation 30 (LODR)-Credit Rating

    Revision in Credit Rating of a Material Subsidiary

    Insider Trading / SAST
    Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

    The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship Ltd

    Insider Trading / SAST
    Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011.

    The Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 on September ....

    Insider Trading / SAST
    Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.

    The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on September 09, 2026 for Union (Mauritius) Holdings Ltd

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Dispatch of Notice of 18th Annual General Meeting and Integrated Annual Report for the financial year 2025-26

    Filed with BSE (scrip 540975); the last 45 days. Documents open at bseindia.com.

    Documents

    Credit ratings

    Documents open at BSE or the rating agency that issued them.

    Sourced from the company's NSE XBRL filing dated 7 Nov 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.

    FAQ

    Aster DM Quality Care: common questions

    Answered from the figures on this page.

    Aster DM Quality Care last traded at ₹731.00 (NSE, as of 18 Nov 2026). The last session moved it down 0.94%.

    Aster DM Quality Care is valued at about ₹63,646 crore (NSE, as of 18 Nov 2026).

    Aster DM Quality Care trades at a price-to-earnings ratio of 93.00 (NSE, as of 18 Nov 2026). The P/E compares the share price with earnings per share, so it is only comparable between companies in the same industry.

    Aster DM Quality Care has traded between ₹519.10 and ₹891.30 over the past 52 weeks, to 18 Nov 2026. It is currently 57% of the way up that range.

    Aster DM Quality Care (ASTERDM) is classified under Pharma on this site's screener.